PACT Pharma

PanCancerT

This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.

Swarm Oncology

This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.

Lyell Immunopharma

This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

OverT Bio

This company develops engineered cell therapies and genetic screening platforms to treat patients with solid tumour cancers.

CTRL Therapeutics

This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.

3T Biosciences

The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.